Treatment With Dinutuximab in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma

Conditions:   Ganglioneuroblastoma, Nodular;   High-Risk Neuroblastoma Interventions:   Biological: Dinutuximab;   Drug: Irinotecan;   Drug: Isotretinoin;   Biological: Sargramostim;   Drug: Temozolomide Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials